Clin2
NCT07331545Likely a fitNot yet recruiting

Testing safety of QL2401 in healthy Chinese adults

Metabolic Dysfunction-Associated Steatohepatitis(MASH)

Treatments studied

Part of Hormones & metabolism clinical trials.

This trial tests a new medicine called QL2401 in healthy adults to see if it is safe and how the body processes it. If you are a generally healthy Chinese adult aged 18 to 45, you may be able to help researchers understand this drug's effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
70 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You are a healthy adult between 18 and 45 years old.
  • You have a body weight of at least 45 kg (about 100 lbs) for women or 50 kg (about 110 lbs) for men, with a BMI between 18.5 and 32.5.
  • You do not have any serious ongoing health conditions like diabetes, heart disease, liver problems, or chronic stomach issues.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.
  • You have not used any prescription medications (except routine vitamins or birth control) in the last 2 weeks.
  • You are willing to use contraception and follow all study procedures.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07620366Not yet recruiting· Phase 2
Testing QL2401 for Fatty Liver Disease with Scarring

This study tests a new drug called QL2401 to see if it can improve fatty liver disease (MASH) in people who also have diabetes, obesity, or related conditions. The drug is designed to reduce liver fat and slow scarring.

NCT07016633Not yet recruiting· Phase 1/Phase 2
Testing IMM-H014 for metabolic liver disease

This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.

Changchun, Jilin
NCT07145151Recruiting· Phase 2
Studying UBT251 for MASH liver disease

This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.

Beijing, Beijing Municipality
NCT07327281Recruiting· Phase 1
Testing TQF3250 in healthy adults

This trial tests a new oral medication (TQF3250) in healthy adults to see how safe it is and how the body processes it. If you are a generally healthy Chinese volunteer, you may be able to help researchers learn about this potential treatment.

Nanjing, Jiangsu
NCT07581951Not yet recruiting· Phase 3
Study of HSK31679 for people with MASH (liver scarring)

This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.

NCT06575400Recruiting· Phase 1
Testing tolerance of BI 3804379 in healthy people and MASH patients

This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.

Edegem

Hear when a new Metabolic Dysfunction-Associated Steatohepatitis(MASH) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.